IVERIC bio (ISEE) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results
August 4, 2021 6:30 AM EDT- FDA Agreement Under Special Protocol Assessment (SPA) Received for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Zimura GATHER2 Enrollment Complete; Retention Exceeding Expectations, with Injection Fidelity Rate Target of Greater than 90% -
- GATHER1 18 Month Post-Hoc Analyses Show Zimura 2 mg Has the Potential to Have an Impact on Earlier Stages of Dry AMD Prior to Geographic Atrophy -
- Conference Call and Webcast Today, August 4, 2021, at 8:00 a.m. ET -
NEW YORK--(BUSINESS... More
